Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the NAS ...